174 related articles for article (PubMed ID: 11295102)
1. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
Gali-Muhtasib HU; Haddadin MJ; Rahhal DN; Younes IH
Oncol Rep; 2001; 8(3):679-84. PubMed ID: 11295102
[TBL] [Abstract][Full Text] [Related]
2. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents.
Diab-Assef M; Haddadin MJ; Yared P; Assaad C; Gali-Muhtasib HU
Mol Carcinog; 2002 Apr; 33(4):198-205. PubMed ID: 11933073
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic cells in tumors as a target for cancer therapy.
Gali-Muhtasib HU; Diab-Assef M; Haddadin MJ
J Med Liban; 2002; 50(4):175-9. PubMed ID: 15298478
[TBL] [Abstract][Full Text] [Related]
4. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
6. Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells.
Gali-Muhtasib HU; Diab-Assaf M; Haddadin MJ
Cancer Chemother Pharmacol; 2005 Apr; 55(4):369-378. PubMed ID: 15538569
[TBL] [Abstract][Full Text] [Related]
7. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
Buravchenko GI; Scherbakov AM; Dezhenkova LG; Bykov EE; Solovieva SE; Korlukov AA; Sorokin DV; Monzote Fidalgo L; Shchekotikhin AE
Bioorg Chem; 2020 Nov; 104():104324. PubMed ID: 33142432
[TBL] [Abstract][Full Text] [Related]
8. Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.
Gali-Muhtasib H; Sidani M; Geara F; Mona AD; Al-Hmaira J; Haddadin MJ; Zaatari G
Int J Oncol; 2004 May; 24(5):1121-31. PubMed ID: 15067333
[TBL] [Abstract][Full Text] [Related]
9. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
Naylor MA; Stephens MA; Nolan J; Sutton B; Tocher JH; Fielden EM; Adams GE; Stratford IJ
Anticancer Drug Des; 1993 Dec; 8(6):439-61. PubMed ID: 8286012
[TBL] [Abstract][Full Text] [Related]
10. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
11. Quinoxaline 1,4-dioxide: a versatile scaffold endowed with manifold activities.
Carta A; Corona P; Loriga M
Curr Med Chem; 2005; 12(19):2259-72. PubMed ID: 16178784
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
13. Revision of the Regioselectivity of the Beirut Reaction of Monosubstituted Benzofuroxans with Benzoylacetonitrile. 6-Substituted quinoxaline-2-carbonitrile 1,4- dioxides: Structural Characterization and Estimation of Anticancer Activity and Hypoxia Selectivity.
Buravchenko GI; Scherbakov AM; Korlukov AА; Dorovatovskii PV; Shchekotikhin AE
Curr Org Synth; 2020; 17(1):29-39. PubMed ID: 32103715
[TBL] [Abstract][Full Text] [Related]
14. Systematic and Molecular Basis of the Antibacterial Action of Quinoxaline 1,4-Di-N-Oxides against Escherichia coli.
Cheng G; Li B; Wang C; Zhang H; Liang G; Weng Z; Hao H; Wang X; Liu Z; Dai M; Wang Y; Yuan Z
PLoS One; 2015; 10(8):e0136450. PubMed ID: 26296207
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
16. An appraisal on synthetic and pharmaceutical perspectives of quinoxaline 1,4-di-N-oxide scaffold.
Agrawal N; Bhardwaj A
Chem Biol Drug Des; 2022 Sep; 100(3):346-363. PubMed ID: 35610776
[TBL] [Abstract][Full Text] [Related]
17. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
18. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents.
Ortega MA; Morancho MJ; Martínez-Crespo FJ; Sainz Y; Montoya ME; López de Ceráin A; Monge A
Eur J Med Chem; 2000 Jan; 35(1):21-30. PubMed ID: 10733600
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.
Hu Y; Xia Q; Shangguan S; Liu X; Hu Y; Sheng R
Molecules; 2012 Aug; 17(8):9683-96. PubMed ID: 22890172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
